Guideline / position statementindependent cross-checkabstract checked★ key study I-FAST-105 standard review
European fatty-liver guideline
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Overview
European Association for the Study of the Liver (EASL) et al.. J Hepatol 2024 · PMID 38851997 · DOI 10.1016/j.jhep.2024.04.031
European liver, diabetes and obesity societies recommend weight loss through diet change and exercise, plus drugs or surgery for some patients.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Guide MASLD care.
- How was the study done?
Expert guideline based on evidence review.
- How many people, animals or samples were studied?
not applicable
- What was actually found?
Lifestyle-based weight loss, incretin drugs, bariatric surgery and resmetirom are recommended options.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Fatty liver has several proven treatments; no single diet pattern is required.
- What are the study's limitations?
Only the abstract was read.
- What does it say about Elawady's specific claim?
Refutes 'the only treatment'.
- Do the results apply to Germany and Europe?
Directly applicable in Europe; Egyptian practice largely follows similar guidance.
- What can explicitly not be concluded from this study?
Detailed ranking of dietary patterns.
Scientific in-depth review
1. Full reference
- Authors
- European Association for the Study of the Liver (EASL) et al.
- Journal
- J Hepatol
- Year
- 2024
- Identifier
- PMID 38851997 DOI 10.1016/j.jhep.2024.04.031
- Verification
- verified – PubMed efetch 2026-10-26; Crossref update-to/updated-by check
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Several authors report industry consulting/speaking (listed in record).
2. Research question
How should MASLD be defined, screened, diagnosed and treated?
3. Study design and population
- Study design
- Guideline / position statement – Joint European clinical practice guideline (EASL, EASD, EASO)
- Population
Adults with MASLD
- Country
Europe
- Period
not stated in abstract
- Sample size
not applicable
- Inclusion and exclusion criteria
not stated in abstract
4. Methods and endpoints
- Exposure / intervention
Lifestyle modification, incretin-based therapy, bariatric surgery, resmetirom
- Comparator
not applicable
- Endpoints
Recommendations
- Statistical methods
not applicable
5. Actual results
- Results
Abstract: in adults with MASLD, lifestyle modification - including weight loss, dietary changes, physical exercise and discouraging alcohol - and optimal management of comorbidities including incretin-based therapies (e.g. semaglutide, tirzepatide) if indicated, is advised; bariatric surgery is an option in MASLD with obesity; resmetirom should be considered in non-cirrhotic MASH with fibrosis stage >=2 where approved.
- Absolute risks
not reported
- Authors' conclusion
Multiple evidence-based options exist; weight loss through lifestyle change is central; drugs and surgery for selected patients.
6. Strengths
- Multisociety European guideline
- Current (2024)
7. Weaknesses
- Abstract only accessed; specific statements on intermittent fasting not verified
- Industry relationships of some authors
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline; AGREE II not formally applied.
9. Assessment of the statistical interpretation
Not applicable.
10. Relevance to the specific claim
Lists several effective treatments for fatty liver (weight loss by any dietary change, exercise, drugs, surgery); none is fasting-specific.
11. Independent contrary findings
12. Transferability to Germany and Europe
Universal biology; applies in Europe and Egypt.
13. Overall methodological judgement
Guideline evidence that intermittent fasting is not 'the only treatment' for fatty liver.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | not replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |